Pharmacogenomics (PGx) focuses on the influence of genetic variations on drug response (Just et al., 2017). PGx is progressing from identifying drug-gene pairs to assimilating into clinical practice (Frick et al., 2016). A recent study conducted in Singapore observed that 30% of adverse drug reactions (ADRs) were caused by at least one drug with a PGx clinical annotation, suggesting the potential to prevent ADR occurrence via PGx testing (Chan et al., 2016). Despite PGx testing demonstrating its potential to enhance medication safety and efficacy (Dunnenberger et al., 2015), its utility in clinical practice has been suboptimal (Chan et al., 2017), specifically in Asia (Lee et al., 2017). The lack of PGx education is an often-cited barrier to the widespread implementation of PGx (Mccullough et al., 2011; Kisor et al., 2015; Luzum and Luzum, 2016; Kisor and Farrell 2019).
Read more about it here.
